LegitScript will certify sellers of BPC-157 and five other peptides
From November 2, LegitScript no longer refuses certification to sellers of BPC-157, TB-500, KPV, MOTS-c, Epitalon or Semax, if the product follows HHS's new policy. Which forms qualify, and what the seal does not mean.
On November 2, 2026, LegitScript changed its review rules. Selling one of the six peptides in HHS's new enforcement-discretion policy no longer stops a business from getting or keeping LegitScript certification, as long as the product meets that policy's conditions [1].
LegitScript is a private company whose certification seal appears on many telehealth sites, including several we review. It certifies; it does not regulate. Nothing about the law or the evidence changed on November 2.
The six peptides at a glance
What counts is the form. HHS ties each peptide to the routes it lists, and LegitScript follows that list [1][2].
| Peptide | Form that qualifies | Does not qualify |
|---|---|---|
| BPC-157 | Injection, oral, topical | Blends, such as with TB-500 or semaglutide |
| TB-500 | Injection | Any other form |
| Epitalon | Injection, in courses | Any other form |
| MOTS-c | Injection | Any other form |
| Semax | Nasal spray | Injection |
| KPV | Oral, topical | Injection |
"Injection" here means under the skin or into a muscle. For all six, the product has to be a single peptide, and it cannot come in an injector pen.
Three rules you will see on menus
- One peptide per product. BPC-157 with TB-500, or BPC-157 with semaglutide, does not qualify [1].
- Syringes, not pens. The only device that may come packed with the product is an FDA 510(k)-cleared syringe. An injector pen does not meet that condition [1].
- Oral forms need data. The compounder must hold documentation that the specific oral formulation is adequately absorbed in humans [1][2]. We know of no published human data of that kind for oral BPC-157 or oral KPV.
Who is covered: a licensed 503A pharmacy or physician compounding for a named patient, under the ten conditions of the HHS policy of October 28 [2][3]. LegitScript's review looks at the ingredient, the formulation, the route, the compounding facility and the supply chain. Outsourcing facilities under section 503B are not covered [1].
Everything else stays where it was. Other peptides, and formulations outside the policy, remain a barrier to certification [1]. That includes drugs FDA says cannot be compounded at all under federal law, such as retatrutide and cagrilintide [4].
What the seal now tells you
On the site of a seller offering one of these six peptides, a current LegitScript seal means the business passed a review that looked at that offering against the policy's conditions.
It does not mean the product is FDA-approved. None of the six is approved for any use, FDA's own reviewers proposed against listing all of them, and the human evidence behind most of the uses sold is thin. Our peptide pages, linked in the table above, set out what is known.
A seal is an image, and an image can be copied. LegitScript runs a public certification lookup where you can check a seller's domain yourself.
If a certified seller lists a premixed blend, or one of these peptides in an injector pen, that product sits outside both the HHS policy and LegitScript's stated approach. Ask which pharmacy compounds it and on what basis.
What it does not change
Advertising platforms and payment companies set their own rules. LegitScript says its certification does not override them or guarantee access to their services, and that platforms updating their policies may move on a different timeline [1].
The policy underneath is not settled. Comments on it close November 13 [3], and HHS says it may revisit the policy in whole or in part [2]. LegitScript tells businesses to be ready to adjust what they sell if the policy is revised or withdrawn [1].
And websites selling vials labelled "research use only" are untouched by any of this. They are not compounding for a named patient, and FDA has kept sending them warning letters.
For where each peptide stands in US law, see our regulatory tracker.
References
- LegitScript — "HHS's Peptide Compounding Policy: What Healthcare Businesses Need to Know," Naomi Moono, November 2, 2026.
- HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list) and Appendix B (identities, routes and justifications).
- Federal Register — HHS, notice of availability of that policy, 91 FR 68526–68527, FR Doc. 2026-22192, published October 30, 2026.
- FDA — "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" (retatrutide and cagrilintide), content current October 1, 2026.
Editorial note: Informational only — not medical advice. None of these peptides is FDA-approved, and LegitScript certification is not FDA approval. Decisions about any compounded peptide should be made with a licensed healthcare provider familiar with your medical history. Last reviewed November 2026.